Eculizumab is an expensive, humanised monoclonal antibody against the terminal complement protein C5. The drug was patented in 2007, and has since been used and approved for two rare diseases, paroxysmal nocturnal haemoglobulinuria and atypical haemolytic ureamic syndrome. Additionally, eculizumab has been used off-label, which constitutes up to a half of its use in some countries,¹ for at least 25 different conditions. Refractory and generalised myasthenia gravis with anti-acetylcholine receptor antibodies is a rare disease that involves the complement system and for which eculizumab has a potential effect.

中文翻译：

---

Eculizumab：重症肌无力的治疗选择吗？

Eculizumab是一种针对末端补体蛋白C5的昂贵的人源化单克隆抗体。该药物于2007年获得专利，此后已用于并批准用于两种罕见疾病：阵发性夜间血红蛋白尿和非典型溶血性尿毒症。此外，依库珠单抗已被用于标示外，其构成了它的使用在一些国家半，¹至少25个不同的条件。带有抗乙酰胆碱受体抗体的难治性和广义重症肌无力是一种罕见的疾病，涉及补体系统，依库丽单抗可能具有潜在作用。